To read this content please select one of the options below:

Applying marketing conventions on pharmaceutical generics: an analysis of Starpram brand from Maple Pharmaceuticals

Shoaib M. Farooq Padela (Department of Marketing, Auckland University of Technology, Auckland, New Zealand)
Jawaid Ahmed Qureshi (Department of Management Science, Shaheed Zulfikar Ali Bhutto Institute of Science and Technology, Dubai, United Arab Emirates)
Salman Bashir (Department of Business Administration, Shah Abdul Latif University, Khairpur, Pakistan)

Publication date: 13 December 2019

Abstract

Learning outcomes

Learning outcomes (objectives and outcomes) are as follows: to understand the brand positioning, brand building and category extension decisions of a pharmaceutical brand (operative in one of the most competitive and regulated industries in a developing country); to analyze the outcomes of decisions pertaining strategic sales, branding, marketing and strategic restructuring to overcome the challenges of growth; and to design strategic solutions for developing brand equity.

Case overview/synopsis

This case explores the strategy of launching and establishing a pharmaceutical brand in an industry that tends to be a highly technical and the most regulated industry. It depicts market research data, industry analysis, stiff competition and regulatory affairs, and elaborates various strategic decisions taken by the company. The primary data for the case is accumulated through in-depth interviews from six industry experts on pharma marketing who were well acquainted with Maple Pharma and secondary data is gleaned from substantive literature. Maple Pharmaceuticals launched Starpram, a high-growth, high-potential generic antidepressant brand (in the central nervous system category) containing Escitalopram molecule/chemical. It had expertise cum competitive advantage in cardiovascular and anti-diabetic streams, but such initiative appeared category extension, with the intention to diversify risk and expand the company to achieve greater economies of scale. The first year sales revenue for Starpram appeared too bleak to spur further product inaugurations. Consequently, strategic overhaul transpired to establish the brand in the highly fragmented pharmaceutical industry. The firm lacked experience in anti-depressants category, coupled with poor sales, marketing mix and overall marketing strategy. Eventually, the management exercised strategic restructuring to establish brand equity and observed growth.

Complexity academic level

Study levels/Applicability graduate (MBA), MS, PhD (management sciences).

Supplementary materials

Teaching Notes are available for educators only. Please contact your library to gain login details or e-mail support@emeraldinsight.com to request teaching notes.

Subject code

CSS 8: Marketing.

Keywords

Acknowledgements

Disclaimer. This case is written solely for educational purposes and is not intended to represent successful or unsuccessful managerial decision-making. The authors may have disguised names, financial and other recognizable information to protect confidentiality.

Citation

Padela, S.M.F., Qureshi, J.A. and Bashir, S. (2019), "Applying marketing conventions on pharmaceutical generics: an analysis of Starpram brand from Maple Pharmaceuticals", , Vol. 9 No. 4. https://doi.org/10.1108/EEMCS-11-2019-0294

Publisher

:

Emerald Publishing Limited

Copyright © 2019, Emerald Publishing Limited

Related articles